Ocular Therapeutix, Inc. (NASDAQ:OCUL) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other equities analysts have also recently commented on OCUL. BTIG Research cut shares of Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research note on Friday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 price target on shares of Ocular Therapeutix in a research note on Friday, May 5th. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Tuesday, May 16th. Morgan Stanley cut shares of Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price target for the company. in a research note on Friday, June 23rd. Finally, HC Wainwright initiated coverage on shares of Ocular Therapeutix in a research note on Wednesday, July 26th. They issued a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $20.11.

Ocular Therapeutix (OCUL) opened at 5.77 on Friday. The company has a 50-day moving average of $8.37 and a 200 day moving average of $8.77. Ocular Therapeutix has a 52 week low of $4.04 and a 52 week high of $11.91. The company’s market cap is $167.49 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.10. Ocular Therapeutix had a negative return on equity of 80.26% and a negative net margin of 2,620.06%. The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.51 million. During the same period in the prior year, the firm earned ($0.35) EPS. On average, equities analysts forecast that Ocular Therapeutix will post ($2.19) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ValuEngine Downgrades Ocular Therapeutix, Inc. (OCUL) to Sell” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/06/valuengine-downgrades-ocular-therapeutix-inc-ocul-to-sell.html.

Several large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Ocular Therapeutix during the first quarter worth about $3,394,000. GWM Advisors LLC acquired a new stake in shares of Ocular Therapeutix during the first quarter worth about $381,000. NEXT Financial Group Inc acquired a new stake in shares of Ocular Therapeutix during the first quarter worth about $480,000. Parametric Portfolio Associates LLC boosted its stake in shares of Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 401 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Ocular Therapeutix by 24.9% in the first quarter. Bank of New York Mellon Corp now owns 88,736 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 17,679 shares during the period. 65.05% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.